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Abstract 
Background: There is a clear need for systematic appraisal of models/factors predicting colorectal 
cancer (CRC) metastasis and recurrence because clinical decisions about adjuvant treatment are taken 
on the basis of such variables.  
Methods: We conducted an umbrella review of all systematic reviews of observational studies 
(with/without meta-analysis) that evaluated risk factors of CRC metastasis and recurrence. We also 
generated an updated synthesis of risk prediction models for CRC metastasis and recurrence. We 
cross-assessed individual risk factors and risk prediction models. 
Results: Thirty-four risk factors for CRC metastasis and 17 for recurrence were investigated. 12/34 
and 4/17 risk factors with p<0.05 were estimated to change the odds of the outcome at least 3-fold. 
Only one risk factor (vascular invasion for lymph node metastasis [LNM] in pT1 CRC) presented 
convincing evidence. We identified 24 CRC risk prediction models. Across 12 metastasis models, six 
out of 27 unique predictors were assessed in the umbrella review and four of them changed the odds of 
the outcome at least 3-fold. Across 12 recurrence models, five out of 25 unique predictors were 
assessed in the umbrella review and only one changed the odds of the outcome at least 3-fold. 
Conclusions:  This study provides an in-depth evaluation and cross assessment of 51 risk factors and 
24 prediction models. Our findings suggest that a minority of influential risk factors are employed in 
prediction models, which indicates the need for a more rigorous and systematic model construction 
process following evidence-based methods.  
Keywords: Colorectal cancer, Metastasis, Recurrence, Risk factors, Risk prediction models, 
Umbrella review 
 
 
Background  
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Around 20-25% of patients with colorectal cancer (CRC) present with metastasis at initial diagnosis, 
whilst patients who are apparently cancer-free on investigation at diagnosis subsequently develop 
locoregional recurrence (18%), distant (78%) recurrence or both (4%) (1). Metastasis occurs when 
cancer cells from the original tumour are able to proliferate in local, regional or distant tissues, lymph 
nodes or organs via lymphatic, blood or even trans-coelomic spread (2). CRC recurrence is defined as 
local, regional and distant metastatic recurrence after a disease-free period (3). Local recurrence refers 
to CRC relapse that occurs at the site of original surgical resection (4), whilst regional recurrence 
occurs at draining lymph nodes and/or lateral pelvic lymph nodes (3). Distant metastatic recurrence 
involves the liver (accounts for 40%-50% of metastases), lung (accounts for 10-20% of metastases), 
the peritoneum, the ovaries, the adrenal glands, the bone, and the brain (1, 5). It is estimated that 5-
year survival rates are around 90%, 70% and 10% for CRC localized, regional and distant metastatic 
stages (6).  
Validating individual risk factors and even more so multivariable prediction models of multiple risk 
factors for local, regional or distant metastasis and recurrence is crucially important as these could 
guide management of the primary tumour and provide prognostic information for patients and their 
cancer clinicians. Prediction models may be more successful if they consider the most informative 
factors. This knowledge may eventually prove useful in managing CRC treatment with better-
informed patient choices. Understanding the underlying validity and predictive performance of risk 
factors for locoregional recurrence is particularly relevant, given progressive moves towards organ-
preserving approaches such as endoscopic resection (EMR), trans-anal microscopic surgery (TEMS) 
and neo-adjuvant chemoradiotherapy for rectal cancer (1), since organ preservation may be at the 
expense of elevated recurrence rates. The corollary also applies since the risk-benefit ratio of extensive 
loco-regional surgery and/or radiotherapy may be detrimentally impacted by future distant metastases.   
A number of systematic reviews (with/without meta-analyses) have investigated existing risk factors 
for CRC metastasis and recurrence (7-10). However, there is a need for a comprehensive evaluation of 
the available epidemiological evidence. Here, we conducted an umbrella review to identify and 
evaluate associations between risk factors and risk of CRC metastasis and recurrence. We also 
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systematically collected and evaluated predictive models on CRC prognostic outcomes. We then 
conducted a comparative cross-assessment between the identified risk factors and the predictors 
employed in risk prediction models to examine to what extent predictive models include the most 
influential factors. 
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Methods 
Protocol 
The study protocol was developed in accordance with the reporting guidance in the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement (11).  
Umbrella review of systematic reviews (with/without meta-analyses) of risk factors 
Literature search and eligibility criteria  
A systematic search was performed in PubMed, Cochrane Library (Wiley), Web of Science (Thomson 
Reuters) and EMBASE (Ovid) from inception to 7th October 2019, to identify systematic reviews of 
observational studies with or without a meta-analysis that evaluated the associations between risk 
factors and risk of metastasis and recurrence in CRC ( Additional file 1: Table S1). We further hand-
searched reference lists of the retrieved eligible publications to identify additional relevant studies. All 
identified publications went through a parallel review of the title, abstract and full text (performed by 
W.X. and Y.M. independently) based on predefined inclusion and exclusion criteria following 
‘PICOS’. In particular, we included human participants from observational studies with no restriction 
to settings. Conversely, animals, in vitro and in vivo experiments were excluded. For study outcomes, 
we included CRC metastasis (local, regional or distant metastasis in tissues, lymph nodes or organs at 
diagnosis) and CRC recurrence (local, regional or distant metastatic recurrence in tissues, lymph nodes 
or organs after a disease-free period). For study design, we included systematic reviews of 
observational studies with or without meta-analysis. Conversely, literature reviews, individual 
observational studies, systematic reviews and meta-analyses that investigated the evidence on the 
efficacy of pharmaceutical drugs and therapeutic procedures were excluded. We included publications 
in peer-reviewed journals and therefore gray literature, comments, conference abstracts, and 
interviews were excluded. 
Data extraction  
6 
 
Data were extracted by one investigator (W.X.) and checked by a second investigator (Y.H.). For each 
included meta-analysis, the following items were extracted: study citation details, number of studies 
included, study design, study population, number of events and size of total population, risk factors, 
outcomes examined, reported summary meta-analytic estimates (e.g. risk ratio [RR], odds ratio [OR], 
hazard ratio [HR], the corresponding 95% confidence interval [95% CI], p-value and heterogeneity 
measures), instrument applied for quality and risk of bias assessment of component studies, and 
quality assessment result. The following items were further extracted from the individual component 
studies: study citation details, study design, study population, risk factors, outcomes examined, 
number of events and size of total population in exposed and unexposed groups, effect size and 95% 
CI.  
Evidence synthesis and evaluation  
First, when two or more meta-analyses examining associations between the same risk factor and the 
same outcome were identified, the most recent meta-analysis of prospective cohort studies with the 
largest event number was prioritized and retained for further analysis. We also compared whether the 
results reported in overlapping meta-analyses were concordant in terms of direction, statistical 
significance and association magnitude.  
Second, we estimated the following metrics for each unique meta-analysis: 1) The summary effect size 
along with 95% CI was estimated based on random-effects models (DerSimonian and Laird (DL) 
when the number of component studies was five or more and the Hartung-Knapp-Sidik-Jonkman 
(HKSJ) when the number of component studies was less than five (12-13). 2) Heterogeneity was 
assessed by the I² statistic (14). 3) The 95% prediction interval was estimated. 4) The small study 
effect was estimated by the Egger’s regression asymmetry test (15). 5) Excess significance was 
assessed by a chi-square test (16). Based on these metrics and by applying a set of pre-defined criteria 
( Additional file 1: Table S8), we evaluated the credibility of the evidence for each risk factor and 
categorized the evidence as convincing, highly suggestive, suggestive or weak (17-18).  
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Lastly, for all meta-analyses that statistically represented at least 3-fold changes in the odds of the 
outcome, we evaluated the methodological quality and risk of bias based on the Assessment of 
Multiple Systematic Reviews 2.0 (AMSTAR 2.0) checklist (19).  We used an odds ratio of 3.0 as a 
threshold for what is a substantially large effect. There is no consensus on what an optimal threshold 
might be, but values between 2 and 5 are proposed typically (74).  
Sensitivity analysis  
We re-ran all meta-analyses by evaluating the outcome definitions of each individual component study 
reclassifying the outcomes to (i) CRC metastasis at presentation; (ii) CRC local recurrence after a 
disease-free period; and (iii) CRC distant recurrence after a disease-free period. 
Comparative cross-assessment of risk factors and risk prediction models 
We performed a comparative cross-assessment between risk factors evaluated in the umbrella review 
and risk predictors included in existing prediction models. A recently published systematic review 
conducted by our team (73) investigated a total number of 15 prediction models for prediction of 
metastasis and recurrence in CRC patients with surgical resection (metastasis: N=6; recurrence: N=9). 
We updated the original search to identify studies developing and/or validating risk prediction models 
to predict metastasis and recurrence in all CRCs, with no restriction on whether the tumour was 
resected. We performed a systematic search in PubMed from inception to 7th October 2019 to identify 
eligible studies. We extracted data relevant to study design, study population, prediction outcome, 
prediction time horizon, predictors, model performance and model presentation from each included 
study. We created a catalog of all variables that had been included across CRC metastasis prognostic 
models and separately across CRC recurrence prognostic models (presented in the same order as in the 
respective tables). We then assessed whether the included risk predictors were evaluated or not in the 
umbrella review described above. If yes, we also recorded the magnitude of the summary relative risk 
(typically odds ratio), and noted how many of those represented at least 3-fold changes in the odds of 
the outcome and how many had convincing or highly suggestive evidence in our assessment.     
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All statistical analyses were conducted in Stata, version 14.0 (StataCorp), and R, version 3.3.0 (R 
Foundation for Statistical Computing). 
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Results 
Literature Review  
A total of 2,033 publications were retrieved from the systematic search in four databases. Eventually, 
43 publications met all inclusion criteria (Figure 1, Additional file 1: Table S2) and that included 9 
systematic reviews (metastasis: N=7; recurrence: N=2) and 81 meta-analyses (metastasis: N=61; 
recurrence: N=20; Additional file 1: Table S3 and Table S4) of observational studies. A total of 18 
overlapping meta-analyses that examined associations between the same risk factor and the same 
outcome were identified ( Additional file 1: Table S5). The most recent meta-analysis with the largest 
event number was prioritized. Within the remaining 63 unique meta-analyses, 12 meta-analyses from 
four publications did not report detailed OR, RR or HR in forest plots. Finally, 51 unique meta-
analyses were retained for analysis, which reported 34 unique risk factors for CRC metastasis and 17 
risk factors for recurrence ( Additional file 1: Table S6 and Table S7)  
Meta-analyses of risk factors for CRC metastasis 
Overall, 61 eligible meta-analyses of observational studies investigating risk factors for CRC 
metastasis were identified ( Additional file 1: Table S3). More than one meta-analysis was conducted 
for seven risk factors ( Additional file 1: Table S5). The direction of the summary effect size and the 
presence of nominal statistical significance (P<0.05) of the reported associations in overlapping meta-
analyses were concordant for six (86%) risk factors ( Additional file 1: Table S5).  
A total of 34 unique meta-analyses with available data were retained for further analysis ( Additional 
file 1: Table S6). The median number of included component studies was five (range: 2-41), the 
median number of the total population was 983 (range: 76-10,128), and the median number of events 
was 138 (range: 16-1,808). The meta-analyses reported a wide range of risk factors ( Additional file 1: 
Table S6): 17 histopathological risk factors (50%), 13 biomarkers (38%), three genetic risk factors 
(9%), and one demographic risk factor (3%). Overall, 21 (62%) of 34 unique meta-analyses reported 
effect sizes at P<0.05 (Table 1). Based on the pre-defined credibility criteria, only one (3%) 
histopathological risk factor (vascular invasion for LNM in pT1 CRC) presented convincing evidence 
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(see  Additional file 1: Table S9for the credibility assessment of all identified risk factors). 
Furthermore, 12 of 21 probed risk factors with p<0.05 had an effect size suggesting ≥3-fold change in 
the odds of the outcome, while this was also seen for the point estimates in four of 13 probed risk 
factors where the meta-analysis had p≥0.05 (Table 1).  
Meta-analyses of risk factors for CRC recurrence 
Overall, 20 eligible meta-analyses of observational studies investigating risk factors for CRC 
recurrence were identified ( Additional file 1: Table S4). More than one meta-analysis was conducted 
for three risk factors ( Additional file 1: Table S5). The direction of the summary effect size and the 
presence of nominal statistical significance (P<0.05) of the reported associations between the same 
risk factor and the same outcome in overlapping meta-analyses were concordant for two (67%) risk 
factors ( Additional file 1: Table S5).  
A total of 17 unique meta-analyses with available data were retained for further analysis ( Additional 
file 1: Table S7). The median number of included component studies was six (range: 2-26), the median 
number of the total population was 2773 (range: 252-39,745), and the median number of events was 
551 (range: 57-3,675). The meta-analyses reported a wide range of risk factors ( Additional file 1: 
Table S7): five histopathological risk factors (29%), two biomarkers (12%), one genetic risk factor 
(6%), five clinical risk factors (29%), one comorbidity (6%), and three anthropometric indices (18%). 
Overall, 11 (65%) of 17 unique meta-analyses reported effect sizes at P <0.05 (Table 2). 
No risk factor presented convincing evidence ( Additional file 1: Table S10). In addition, four of 11 
probed risk factors with p<0.05 had an effect size suggesting ≥3-fold change in the odds of the 
outcome (Table 2). 
Methodological quality and risk of bias assessment 
We assessed the methodological quality of 10 publications that included 16 meta-analyses of 
observational studies that statistically represented at least 3-fold changes in the odds of the outcome, 
using the AMSTAR 2.0 checklist ( Additional file 1: Table S13). All assessed studies had more than 
one critical flaw [usually in item 2 (14/16, 88%), 7 (16/16, 100%), and 13 (13/16, 81%)] and several 
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non-critical flaws [usually in items 3 (11/16, 69%), 10 (16/16, 100%), and 12 (16/16, 100%)]. It 
should be noted that all assessed meta-analyses had critically low quality.  Therefore, the credibility of 
the available evidence should be interpreted with caution. 
Sensitivity analysis of redefying the disease outcome groups  
We performed a sensitivity analysis to include individual component studies investigating risk factors 
for metastasis at presentation and re-evaluated the credibility of the evidence ( Additional file 1: 
Table S11). A total of 16 unique meta-analyses including 67 (27%) component studies were retained 
and investigated. The remaining 185 (73%) studies did not illustrate when metastasis was present (i.e. 
at diagnosis or after a disease-free period) and therefore could not be included in this sensitivity 
analysis. Based on the pre-defined criteria, no risk factor presented convincing evidence.  
Similarly, a sensitivity analysis was performed to include individual component studies investigating 
risk factors for local or distant recurrence ( Additional file 1: Table S12). A total of 13 unique meta-
analyses composed of 81 (58%) component studies (including five meta-analyses investigating distant 
metastasis after a period of being disease-free) were retained and investigated. The remaining 59 
(42%) studies did not separate local or distant recurrence and therefore could not be included in our 
sensitivity analysis. Furthermore, no risk factor presented convincing evidence ( Additional file 1: 
Table S12). 
Comparative cross-assessment between risk factors evaluated in the umbrella review and 
risk predictors applied in existing prediction models 
Prediction models for CRC metastasis  
Twelve prognostic models have been developed for prediction of CRC metastasis (49-60) (Table 3). 
The median number of included predictors was four (range 3-9) and 27 unique predictors were 
included in at least one model. Cancer stage (N=9, 75%) was the most commonly used predictor 
variable in the 12 prognostic models. Other common predictors included histopathological risk factors 
such as positive lymph nodes (N=3, 25%), tumour grade or differentiation (N = 2, 17%), and tumour 
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histological type (N=3, 25%); biomarker- carcinoembryonic antigen (CEA) (N=3, 25%); age (N=3, 
25%); gender (N=2, 17%); and clinical treatment such as surgery, chemotherapy, and radiotherapy 
(N=3, 25%). Five models (42%) performed internal validation and four models (33%) were validated 
in external datasets. 
We conducted a cross-assessment between these predictors and 34 risk factors that were evaluated in 
our umbrella review. Six of 27 unique predictors (tumour budding, tumour differentiation, tumour 
size, vascular invasion, submucosal invasion and sex) were evaluated in the umbrella review (Table 
5). The associated ORs for these six risk factors varied from 2.23 to 6.76 and four of them (67%) 
corresponded to ≥3-fold change in the odds of the outcome. Of the remaining 28 risk factors that were 
not employed in prediction models, ORs varied from 0.45 to 6.78, and 13 (46%) represented ≥3-fold 
change in the odds of the outcome.  
In addition, we compared the overlapping outcomes to investigate whether prediction models had 
included influential risk factors (those presented convincing evidence or with 3-fold change in the 
odds of the outcome) when they predicted the same outcomes as those evaluated in the umbrella 
review (Table 6). In total, four overlapping outcomes were found in this cross-assessment (LNM in 
pT1 CRC, LNM in CRC, hepatic metastasis in CRC and distant metastasis in CRC). For only one 
outcome (LNM in pT1 CRC), two prognostic models (49, 55) included four risk predictors that were 
also evaluated in the umbrella review, two of which corresponded to ≥3-fold change in the odds of the 
outcome (tumour budding, tumour differentiation).  
Prediction models for CRC recurrence  
Twelve prognostic models (61-72) were developed for prediction of CRC recurrence (Table 4). The 
median number of risk predictors applied in 12 prognostic models was five (range 2-8) and 25 
uniquepredictors were included in at least one model.  AJCC (TNM) cancer stage was the predictor 
variable (N=7, 58%) used in the majority of CRC recurrence risk prediction models. Other common 
predictor variables included histopathological risk factors such as positive lymph nodes (N=5, 42%), 
tumour grade or differentiation (N = 4, 33%), and tumour size (N=4, 33%); biomarker-CEA (N=4, 
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33%); cancer location (N=4, 33%); clinical treatment such as surgery, chemotherapy, radiotherapy, 
and transfusion (N=5, 42%). Two models (17%) performed internal validation and 4 models (33%) 
were validated in external datasets. 
In our cross-evaluation, five of 25 unique predictors (intramural vascular invasion, extramural 
vascular invasion, being underweight, being overweight and being obese) were evaluated in the 
umbrella review (Table 5). The associated ORs for these five factors varied from 1.00 to 3.91 and only 
one (20%) (extramural vascular invasion) corresponded to ≥3-fold change in the odds of the outcome. 
Of the remaining 12 factors evaluated in the umbrella review, ORs varied from 0.07 to 5.50, and three 
(25%) represented ≥3-fold change in the odds of the outcome.  
In relation to overlapping outcomes, only one outcome (overall recurrence in CRC) was identified 
(Table 6). However, the prognostic model (65) included risk predictors that were not evaluated in the 
umbrella review (cancer stage, tumour differentiation, and gene signature). Meanwhile, within the 
evaluated nine risk factors for overall recurrence in CRC that were not employed as predictors in this 
model, only two influential risk factors (tumour budding, absence of peritoneal free tumour cells in 
post-resection) had ≥3-fold change in the odds of the outcome.  
  
 
 
 
Discussion 
We initially synthesized and evaluated the evidence of risk factors for CRC metastasis and recurrence. 
Our study comprised 51 unique meta-analyses of observational studies investigating 34 risk factors for 
CRC metastasis and 17 risk factors for recurrence. We also conducted a sensitivity analysis of 29 
unique meta-analyses of risk factors for CRC metastasis at presentation (n=16), CRC local recurrence 
(n=5) and CRC distant recurrence (n=8) using a standardized categorization of the component studies. 
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Furthermore, we updated synthesis of risk prediction models for CRC metastasis (n=12) and 
recurrence (n=12) and then conducted a cross-assessment of individual risk factors evaluated in the 
umbrella review and risk predictors included in existing prediction models, which allowed us to 
examine to what extent predictive models include the most influential factors.  
Main findings and interpretation of the umbrella review  
Meta-analyses for CRC metastasis  
According to our pre-defined criteria for assessing the credibility of the evidence, only one risk factor 
was classified as convincing (vascular invasion for LNM in pT1 CRC), reflecting strong statistical 
significance and no hints of bias. Many studies have demonstrated that the invasion of blood vessels 
leading to tumour cell dissemination and metastasis is a strong risk factor for disease prognosis, which 
is in line with our umbrella review (20-21). Based on our findings, a large proportion of studies 
(17/25, 68%) investigated lymphatic and vascular invasion as separate risk factors, while 32% of 
studies categorized them jointly as lymphovascular invasion. It has been shown though that the 
predictive ability of lymphovascular invasion is lower than of vascular invasion (22).  
Twelve (35%) of 34 probed risk factors for metastasis had an effect size suggesting ≥3-fold change in 
the odds of the outcome with p<0.05. Four of these risk factors (lymphatic invasion for LNM in pT1 
CRC; tumour budding for LNM in pT1 CRC; tumour budding for LNM in all stage CRC; tumour 
size>1cm for LNM in rectal cancer) were classified as highly suggestive. As discussed above, 
lymphatic invasion could be an indicator of tumour cells metastasizing to lymph nodes. This finding 
agrees with three recently published studies manifesting that lymphatic invasion is causally associated 
with the risk of LNM in CRC (33-35). Tumour budding is recognized as a negative prognostic risk 
factor for LNM in CRC and our findings are concordant with previous studies (29-31). Individual 
component studies vary in their definitions of tumour budding (e.g. how many cancer cells comprise a 
tumour bud, and how many buds signify tumour budding) and vary in the pathologic staining methods 
to detect tumour budding (e.g. hematoxylin and eosin [H&E], immunohistochemistry [IHC]). 
Furthermore, a systematic review summarized pathologic methods to detect tumour budding and 
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revealed that all studies even when utilizing different methods showed that tumour budding increases 
the risk of CRC metastasis (32). Notably, substantial between-study heterogeneity (I² >50%) was 
found in the meta-analysis investigating tumour budding for LNM in all CRC stages, indicating that 
this association needs to be interpreted with caution. The observed heterogeneity may be influenced by 
the inclusion of different tumour stages. Finally, tumour size>1 cm is associated with an increased risk 
of LNM in rectal cancer. This largely agrees with the European Society for Medical Oncology 
(ESMO) clinical practice guideline manifesting that a rectal lesion less than 1 cm has a lower risk of 
metastasis and therefore local excision (TEM) is suggested (36).  
Meta-analyses for CRC recurrence  
In regards to 17 probed risk factors for CRC recurrence, four (24%) had an effect size suggesting ≥3-
fold change in the odds of the outcome with p<0.05. None of them presented convincing evidence. 
Three (tumour budding for overall recurrence in CRC; perineural invasion [PNI] for local recurrence 
in rectal cancer; MRI-detected extramural vascular invasion [mrEMVI] for distant metastatic 
recurrence in rectal cancer) were classified as highly suggestive. Our findings suggest that tumour 
budding is a common highly suggestive risk factor for both CRC LNM and overall recurrence. 
However, there is a need for standardization of the histopathological definition of tumour budding 
(22). Another histopathological risk factor: PNI, which is a common pathological feature in rectal 
cancer, strongly signifies local recurrence. Compared to colon cancer, PNI occurs more frequently in 
rectal cancer, since there is a cluster of intensive neural plexuses surrounding the pelvis in the rectum 
(37). The National Comprehensive Cancer Network (NCCN) guidelines also suggest that patients with 
PNI positive are at higher risk of local recurrence (38). However, there is no consensus in the 
definition of PNI positive, with two of the most frequently used definitions being SS-PNI (when 
tumour cells surround at least 33% of the nerve) and TS-PNI (when tumour cells surround any of the 
three layers of the nerve) (39-42). Finally, we found that mrEMVI increases the risk of distant 
metastatic recurrence. EMVI is the venous invasion beyond the muscularis propria, which has long 
been recognized as a risk factor for distant recurrence (43-45). The 5-point MRI-detected EMVI 
scoring system is precise for detecting this invasion and it is recommended as a post-operation follow-
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up strategy in clinical settings (46). In addition, a recently published meta-analysis is also in line with 
our findings, reporting that around 90% of patients with liver metastases are mrEMVI positive (47). 
Sensitivity analysis  
In our effort for a consistent definition of metastasis and recurrence, we re-categorized all the 
component studies to three distinct disease outcomes: metastasis at presentation, local recurrence and 
distant recurrence. This could generate insight into metastasis and recurrence patterns and provide 
investigators and clinicians with a more comprehensive summary of risk factors for these CRC 
prognostic outcomes with clinical significance (48). Our sensitivity analyses reported a dearth of 
convincing evidence.  However, a total of 244 (62%) individual component studies were excluded 
from our sensitivity analyses due to missing information in relation to outcome definition.  
Cross-assessment between risk factors evaluated in the umbrella review and risk predictors 
applied in existing prediction models 
We identified 24 CRC prognostic models for metastasis (n=12) and recurrence (n=12). The majority 
of risk prediction models applied an average of four to five predictor variables. The most commonly 
used predictors were clinic-histopathological (cancer stage, lymph node status) and demographics 
(gender, age) parameters. Seven models were validated internally and eight in external datasets, but 
none of the identified models conducted any impact studies. As for model presentation, the majority of 
models were nomograms (graphical prediction models), and the remaining models were presented as 
formulae, risk scores and calculators. 
In our cross-assessment, we investigated whether the identified prediction models had employed 
influential risk factors (those presented convincing evidence or with 3-fold change in the odds of the 
outcome) when they predicted the same outcomes as those that were evaluated in the umbrella review. 
Across 12 CRC metastasis risk prediction models, five models (49, 50, 52, 55, 56) were on the same 
outcomes (LNM in pT1 CRC, LNM in CRC, hepatic metastasis in CRC and distant metastasis in 
CRC), with only two (49, 55) of these models (on LNM in pT1 CRC) including predictors also 
evaluated in the umbrella review. However, the models’ calibration was poorly reported, which made 
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it difficult to assess the models’ predictive accuracy. Furthermore, one model (55) was externally 
validated to ensure the model’s applicability and generalizability, while, the remaining one (49) did 
not undergo adequate validation to address its potential overfitting. In addition, the remaining three 
models (50, 52, 56) predicting LNM and DM in CRC applied other risk predictors such as cancer 
stage, CEA and alkaline phosphatase (ALP) that were not evaluated in the umbrella review. We 
suggest that risk factors with strong associations with CRC prognosis, such as circulating tumour cells 
and microsatellite instability should be employed following evidence-based methods.  
Across the 12 CRC recurrence risk prediction models, only one model (65) was on an outcome that 
was also evaluated in the umbrella review (overall recurrence in CRC). Unfortunately, we did not find 
overlapping risk factors/predictors. We recommend tumour budding and absence of peritoneal free 
tumour cells in post-resection (≥3-fold change in the odds of the outcome) to be considered as 
predictors.  
Clinical implications and future research 
Identifying and evaluating risk factors with substantial predictive value is of great clinical importance. 
Major clinical decisions are made taking into account expectations and formal or informal predictions 
about major outcomes. Accurate and valid risk prediction could assist with clinical decision-making in 
relation to the extent and mode of surgery and therapy. Ideally, adjuvant treatment would be targeted 
with precision to those most likely to benefit; those most at risk of CRC metastasis/recurrence may 
also have a higher absolute probability of benefit. The majority of patients do not benefit from 
additional therapy aimed at preventing loco-regional or distant relapse before or after surgical 
resection, and yet they may be exposed to the attendant morbidity, cost and false expectation of such 
therapy. Therefore, accurate and valid risk prediction which could impact clinical-decision making is 
crucial. In summary, this umbrella review provides an evidence classification that could help 
clinicians to judge the relative priority of risk factors/predictors’ impact on CRC prognosis and make 
clinical decisions based on more accurate and valid risk prediction. 
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Our findings suggest that efforts to address the limitations of the available evidence could be 
beneficial. Large scale prospective studies are needed to generate evidence less prone to bias and 
allowing better predictive model building and validation. Standardizing the outcome definitions of 
CRC metastasis and recurrence could improve reporting of outcomes that have direct clinical 
relevance. Future risk prediction model research is encouraged to apply rigorous model construction 
processes and to integrate the most influential risk factors based on evidence-based methods. 
Strengths and limitations  
The main strength of this study is that it provides a rigorous critical assessment of the published 
epidemiological evidence on risk factors of CRC metastasis and recurrence, based on pre-defined 
criteria in a transparent and systematic way (17-18). In addition, we updated the synthesis of CRC 
prognostic prediction models, and to our best knowledge, this is the first cross-assessment between 
individual risk factors and risk predictors applied in existing prediction models, to investigate whether 
influential risk factors are employed as predictors. Our findings provide a comprehensive evaluation of 
available evidence that can inform future research on risk factors for CRC prognostic outcomes and 
risk prediction models. 
However, the following potential limitations should be considered. First, umbrella review comprises a 
synthesis of evidence from existing systematic reviews and meta-analyses (23). Therefore, risk factors 
and risk predictors that were not systematically reviewed in the pre-existing literature are not included 
in this umbrella review. These may include some factors that are commonly used in predictive models 
and it highlights the need to perform systematic reviews of the evidence for factors that might be 
routinely or frequently measured. Second, meta-analyses have common defects such as limited 
coverage of the literature search and low quality of the included studies (24-25). Third, this study only 
collected and evaluated evidence from systematic reviews and meta-analyses of observational studies 
published in peer-reviewed journals. This could limit the breadth of our results if research in gray 
literature, conference abstracts, and comments investigated risk factors that were not included in this 
umbrella review.  Furthermore, 77% of meta-analyses included only retrospective studies.  
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Moreover, this study did not evaluate the quality of all individual component studies included in each 
meta-analysis because it is beyond the scope of an umbrella review. Instead, we performed a 
credibility evaluation and risk of bias assessment for meta-analyses that represented at least 3-fold 
changes in the odds of the outcome. Criteria for assessing the evidence from meta-analyses of 
observational studies applied in our umbrella review were based on pre-defined metrics whose 
limitations have been summarized (26-28).  For the outcomes that we studied, one is probably 
interested usually on whether the considered risk factors confer substantial predictive value, rather 
than whether they are causally related to the outcomes. We pre-specified a threshold for the magnitude 
of what might be a relatively large effect size (3-fold change in odds), but this is not absolute. The 
predictive value may depend also on how frequently a given factor is in the evaluated population. 
However, with one exception, all the factors evaluated concurrently in both risk factor meta-analyses 
and in predictive models were pretty common, with prevalence ranging from 16% to 82%.   
We should also acknowledge that although we performed a sensitivity analysis to classify CRC 
metastasis at presentation, local or distant recurrence, a large proportion (62%) of individual 
component studies did not present enough information, such as the timing of metastasis in relation to 
initial diagnosis (i.e. synchronous or metachronous) and local or distant recurrence separately from 
overall recurrence. Finally, we did not evaluate risk factors relevant to clinical interventions such as 
surgery type, chemotherapy, radiotherapy and transfusion. We also could not perform a complete 
comparison between risk factors evaluated in the umbrella review and risk predictors applied in 
existing prediction models because only 11 overlapping risk factors/predictors were identified. 
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Conclusions 
In this umbrella review, we synthesized and evaluated risk factors and risk prediction models of CRC 
metastasis and recurrence. A total of 51 unique risk factors were investigated, convincing evidence 
exists only for the association between vascular invasion and LNM, and even that is restricted to pT1 
tumours. Furthermore, we also conducted a cross-assessment to evaluate individual risk factors and 
risk prediction models. Our findings emphasize the need for a more rigorous and systematic model 
construction process to integrate influential risk factors following evidence-based methods.  
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